PubRank

Antonio Rossi

Author PubWeight™ 140.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003 3.41
2 First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012 3.04
3 Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005 2.11
4 NF-kappaB and virus infection: who controls whom. EMBO J 2003 2.08
5 Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer. Oncology (Williston Park) 2010 2.06
6 Compliance with therapy in hypertensive patients. Intern Emerg Med 2006 1.66
7 Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007 1.60
8 Transcription of Satellite III non-coding RNAs is a general stress response in human cells. Nucleic Acids Res 2007 1.58
9 Comparative genome analysis of Trichophyton rubrum and related dermatophytes reveals candidate genes involved in infection. MBio 2012 1.55
10 Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol 2010 1.53
11 A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum Mol Genet 2005 1.43
12 The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008 1.39
13 Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev 2012 1.37
14 Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem 2006 1.33
15 Treatment of advanced non small cell lung cancer. J Thorac Dis 2011 1.32
16 Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis 2006 1.27
17 Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther 2013 1.26
18 Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007 1.26
19 Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol 2010 1.23
20 Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem 2006 1.22
21 The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist 2007 1.20
22 Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem 2007 1.18
23 Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features. Am J Med Genet A 2010 1.17
24 Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis. Am J Hum Genet 2008 1.15
25 Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007 1.14
26 Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. Am J Hum Genet 2011 1.12
27 Antifungal resistance mechanisms in dermatophytes. Mycopathologia 2008 1.10
28 Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 2010 1.09
29 In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 2009 1.08
30 Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007 1.07
31 Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer 2009 1.07
32 Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003 1.06
33 Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009 1.05
34 Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 2003 1.04
35 Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer 2010 1.03
36 ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013 1.02
37 Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics 2007 1.01
38 Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem 2002 1.01
39 Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells 2012 1.00
40 Lung cancer in the elderly. J Clin Oncol 2007 1.00
41 Molecular diagnosis of analbuminemia: a novel mutation identified in two Amerindian and two Turkish families. Clin Chem 2002 0.99
42 Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009 0.99
43 Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009 0.97
44 The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008 0.96
45 The pH signaling transcription factor PacC mediates the growth of Trichophyton rubrum on human nail in vitro. Med Mycol 2006 0.94
46 Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci 2005 0.94
47 Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin Pharmacother 2013 0.94
48 Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007 0.93
49 Defective proteoglycan sulfation of the growth plate zones causes reduced chondrocyte proliferation via an altered Indian hedgehog signalling. Matrix Biol 2010 0.92
50 Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 2011 0.91
51 A novel splicing mutation causes an undescribed type of analbuminemia. Biochim Biophys Acta 2002 0.90
52 Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009 0.90
53 Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer 2009 0.90
54 Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis. Hum Mutat 2012 0.89
55 A transcript finishing initiative for closing gaps in the human transcriptome. Genome Res 2004 0.89
56 Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer 2010 0.88
57 Self-aggregation of fibrillar collagens I and II involves lysine side chains. Micron 2006 0.88
58 EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. J Thorac Dis 2012 0.88
59 Characterization of a new PEPD allele causing prolidase deficiency in two unrelated patients: natural-occurrent mutations as a tool to investigate structure-function relationship. J Hum Genet 2004 0.88
60 The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs 2010 0.88
61 Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res 2010 0.88
62 Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther 2008 0.88
63 Management of unfit older patients with advanced NSCLC. Cancer Treat Rev 2009 0.87
64 A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. Lung Cancer 2009 0.87
65 Transcriptional profiling reveals the expression of novel genes in response to various stimuli in the human dermatophyte Trichophyton rubrum. BMC Microbiol 2010 0.87
66 A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer 2007 0.87
67 Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010 0.87
68 Role of pH in the pathogenesis of dermatophytoses. Mycoses 2011 0.86
69 Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 2009 0.86
70 New molecular targets in the treatment of NSCLC. Curr Pharm Des 2013 0.86
71 Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf 2011 0.85
72 N-benzyloxycarbonyl-L-proline: an in vitro and in vivo inhibitor of prolidase. Biochim Biophys Acta 2005 0.85
73 A splice variant of the Neurospora crassa hex-1 transcript, which encodes the major protein of the Woronin body, is modulated by extracellular phosphate and pH changes. FEBS Lett 2008 0.85
74 A quantitative and qualitative method for direct 2-DE analysis of murine cartilage. Proteomics 2007 0.84
75 Transcriptional profiling reveals genes in the human pathogen Trichophyton rubrum that are expressed in response to pH signaling. Microb Pathog 2009 0.84
76 Physiological performance of a detergent decellularized heart valve implanted for 15 months in Vietnamese pigs: surgical procedure, follow-up, and explant inspection. Artif Organs 2012 0.84
77 Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr Drug Saf 2016 0.83
78 New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther 2009 0.83
79 A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 2013 0.83
80 First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol 2003 0.83
81 A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. Clin Lung Cancer 2007 0.83
82 Alteration of proteoglycan sulfation affects bone growth and remodeling. Bone 2013 0.83
83 Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer 2012 0.83
84 Matrix disruptions, growth, and degradation of cartilage with impaired sulfation. J Biol Chem 2012 0.82
85 Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 2003 0.82
86 The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets 2012 0.82
87 Subcutaneous angioleiomyoma of the nasal tip. Report of a rare case. In Vivo 2012 0.82
88 Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 2011 0.82
89 Human recombinant prolidase from eukaryotic and prokaryotic sources. Expression, purification, characterization and long-term stability studies. FEBS J 2006 0.82
90 The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Ther Adv Med Oncol 2009 0.81
91 Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: a proteomic approach. J Proteomics 2012 0.81
92 Neutrophil granulocytes uniquely express, among human blood cells, high levels of Methionine-sulfoxide-reductase enzymes. J Leukoc Biol 2007 0.81
93 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy. Eur J Cancer 2011 0.81
94 Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer. Cancer Control 2007 0.81
95 Erlotinib in non-small-cell lung cancer. Expert Opin Pharmacother 2007 0.81
96 Transcription of the Hsp30, Hsp70, and Hsp90 heat shock protein genes is modulated by the PalA protein in response to acid pH-sensing in the fungus Aspergillus nidulans. Cell Stress Chaperones 2011 0.81
97 Factors driving the choice of the best second-line treatment of advanced NSCLC. Rev Recent Clin Trials 2011 0.81
98 rpb2 is a reliable reference gene for quantitative gene expression analysis in the dermatophyte Trichophyton rubrum. Med Mycol 2011 0.81
99 Transcription of the Neurospora crassa 70-kDa class heat shock protein genes is modulated in response to extracellular pH changes. Cell Stress Chaperones 2009 0.81
100 Identification of genes displaying differential expression in the nuc-2 mutant strain of the mold Neurospora crassa grown under phosphate starvation. FEMS Microbiol Lett 2007 0.81
101 Identification of genes differentially expressed in a strain of the mold Aspergillus nidulans carrying a loss-of-function mutation in the palA gene. Can J Microbiol 2008 0.80
102 A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. J Thorac Oncol 2013 0.80
103 Plasma volume and hematocrit changes in recurrent fainters. Clin Auton Res 2003 0.80
104 Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development. Crit Rev Oncol Hematol 2008 0.80
105 The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. Curr Pharm Des 2012 0.80
106 A Mn(II)-Mn(II) center in human prolidase. Biochim Biophys Acta 2012 0.79
107 Novel nonsense mutation causes analbuminemia in a Moroccan family. Clin Chem 2005 0.79
108 Partial Rescue of Biochemical Parameters After Hematopoietic Stem Cell Transplantation in a Patient with Prolidase Deficiency Due to Two Novel PEPD Mutations. JIMD Rep 2011 0.79
109 Transcriptional changes in the nuc-2A mutant strain of Neurospora crassa cultivated under conditions of phosphate shortage. Microbiol Res 2009 0.79
110 Postural hypotension in hypertensive patients. Blood Press 2003 0.79
111 Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 2004 0.79
112 Transcriptional profiling of Neurospora crassa Δmak-2 reveals that mitogen-activated protein kinase MAK-2 participates in the phosphate signaling pathway. Fungal Genet Biol 2013 0.78
113 The transcription of the gene for iso-orotate decarboxylase (IDCase), an enzyme of the thymidine salvage pathway, is downregulated in the pregc mutant strain of Neurospora crassa grown under phosphate starvation. Can J Microbiol 2007 0.78
114 Purification and properties of pi-repressible acid phosphatases from Aspergillus nidulans. Phytochemistry 1998 0.78
115 Emerging drugs targeting PD-1 and PD-L1: reality or hope? Expert Opin Emerg Drugs 2014 0.78
116 Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol 2011 0.78
117 The Microsporum canis genome is organized into five chromosomes based on evidence from electrophoretic karyotyping and chromosome end mapping. Med Mycol 2012 0.78
118 RNA-sequencing analysis of Trichophyton rubrum transcriptome in response to sublethal doses of acriflavine. BMC Genomics 2014 0.78
119 Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J Thorac Oncol 2007 0.78
120 Over-expression of genes coding for proline oxidase, riboflavin kinase, cytochrome c oxidase and an MFS transporter induced by acriflavin in Trichophyton rubrum. Med Mycol 2008 0.78
121 Transcription of Aspergillus nidulans pacC is modulated by alternative RNA splicing of palB. FEBS Lett 2011 0.78
122 Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. J Thorac Oncol 2012 0.77
123 The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 2004 0.77
124 Treatment of severe post-traumatic bone defects with autologous stem cells loaded on allogeneic scaffolds. Surg Technol Int 2012 0.77
125 Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer 2010 0.77
126 Thalidomide in small-cell lung cancer: is it a tombstone? J Clin Oncol 2008 0.77
127 Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol 2008 0.77
128 The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics 2008 0.77
129 Evaluation of ALK gene status in primary lung adenocarcinoma and matched metastases. J Thorac Oncol 2011 0.77
130 In vivo contribution of amino acid sulfur to cartilage proteoglycan sulfation. Biochem J 2006 0.77
131 Improved prolidase activity assay allowed enzyme kinetic characterization and faster prolidase deficiency diagnosis. Clin Chim Acta 2011 0.77
132 The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. Rev Recent Clin Trials 2013 0.77
133 Isolation of transcripts overexpressed in the human pathogen Trichophyton rubrum grown in lipid as carbon source. Can J Microbiol 2011 0.77
134 Irreversible EGFR inhibitors in the treatment of advanced NSCLC. Curr Pharm Des 2014 0.76
135 Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. J Thorac Oncol 2012 0.76
136 Kinetic and structural evidences on human prolidase pathological mutants suggest strategies for enzyme functional rescue. PLoS One 2013 0.76
137 Altered signaling in the G1 phase deregulates chondrocyte growth in a mouse model with proteoglycan undersulfation. J Cell Biochem 2014 0.76
138 Chemotherapy of advanced NSCLC in the elderly. Tumori 2002 0.76
139 Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. Lung Cancer 2002 0.76
140 Insights from a transgenic mouse model on the role of SLC26A2 in health and disease. Novartis Found Symp 2006 0.76
141 Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly? J Clin Oncol 2003 0.76
142 Overcoming Resistance to EGFR Inhibitors in NSCLC. Rev Recent Clin Trials 2016 0.76
143 New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer. Curr Pharm Des 2015 0.75
144 Paclitaxel plus bevacizumab for metastatic breast cancer. N Engl J Med 2008 0.75
145 Transcription of N- and O-linked mannosyltransferase genes is modulated by the pacC gene in the human dermatophyte Trichophyton rubrum. FEBS Open Bio 2012 0.75
146 Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug? J Clin Oncol 2007 0.75
147 The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line? Clin Lung Cancer 2010 0.75
148 Non-small cell lung cancer therapy in the elderly. Clin Adv Hematol Oncol 2011 0.75
149 Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT). Lung Cancer 2009 0.75
150 Fast screening of glycosaminoglycan disaccharides by fluorophore-assisted carbohydrate electrophoresis (FACE): applications to biologic samples and pharmaceutical formulations. Methods Mol Biol 2015 0.75
151 Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer. Clin Lung Cancer 2011 0.75
152 Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies. Curr Clin Pharmacol 2016 0.75
153 Treatment of non-small cell lung cancer and targeted therapies: where are we? Curr Opin Oncol 2005 0.75
154 Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option? Oncology 2010 0.75
155 Disfiguring facial hemangioma compromising labial functionality: a case report. Ann Ital Chir 2013 0.75
156 Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program. Anticancer Res 2004 0.75
157 Optimization of a capillary electrophoretic method to detect and quantify the Gly-Pro dipeptide in complex matrices from long term cultured prolidase deficiency fibroblasts. J Chromatogr B Analyt Technol Biomed Life Sci 2003 0.75
158 Analbuminemia in a Swiss family is caused by a C --> T transition at nucleotide 4446 of the albumin gene. Clin Biochem 2005 0.75
159 Saturable absorption of femtosecond optical pulses in multilayer turbostratic graphene. Opt Express 2016 0.75
160 Oral cytotoxic drugs. Suppl Tumori 2002 0.75
161 Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy? Expert Rev Vaccines 2013 0.75
162 The role of the antiangiogenetic ramucirumab in the treatment of advanced non small cell lung cancer. Curr Med Chem 2016 0.75
163 Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011 0.75
164 Undecanoic acid resistance in filamentous fungi: identification and linkage mapping of the Aspergillus nidulans udaA gene. J Gen Appl Microbiol 2005 0.75
165 A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. Oncology 2002 0.75
166 New insights in drug development for the non-small cell lung cancer therapy. Front Biosci 2008 0.75
167 Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer. Expert Rev Respir Med 2015 0.75
168 Switch maintenance versus second-line treatment in non-small cell lung cancer. J Thorac Oncol 2011 0.75
169 Diastrophic dysplasia sulfate transporter (SLC26A2) is expressed in the adrenal cortex and regulates aldosterone secretion. Hypertension 2014 0.75
170 Responsiveness of skin metastases to CMF in a patient with urothelial carcinoma of the bladder: a case report. Tumori 2003 0.75
171 Treatment of stage I-III non-small-cell lung cancer in the elderly. Oncology (Williston Park) 2006 0.75
172 A single amino acid substitution in one of the lipases of Aspergillus nidulans confers resistance to the antimycotic drug undecanoic acid. Biochem Genet 2008 0.75
173 Corrigendum: NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nat Genet 2017 0.75